LINK-003

LINK-003 is a preclinical-stage therapeutic candidate being developed by LinkGevity for organ preservation. It is part of the company's proprietary Anti-Necrotics™ platform, which represents a first-in-class approach to inhibiting necrosis (uncontrolled cell death). LINK-003 is designed to transform organ transplantation by significantly extending preservation windows, addressing the critical issue of organ shortages. The mechanism of action involves blocking necrosis, which is the primary cause of irreversible damage during organ storage and transplantation. According to the company, the technology has been independently validated to block necrosis by approximately 90%, potentially enabling new preservation techniques and improving the viability of donor organs.